Baylor College of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Baylor College of Medicine sits in the top decile of US sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count).

616 total trials 93 currently recruiting 376 completed early-phase tilt top decile by trial count

Baylor College of Medicine: 616 sponsored US clinical trials, 93 recruiting.

Baylor College of Medicine sponsors 616 registered US clinical trials on ClinicalTrials.gov, 93 of them currently recruiting, and 376 completed. 59 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 7 trials.

Top-decile sponsor footprint

Baylor College of Medicine ranks in the top decile of sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

376 of 452 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

616 total, page 6 of 13

COMPLETED NA

Study of Arginine and Nitric Oxide in Patients With Diabetes

NCT03566524

TERMINATED NA

Coaching and Education for Diabetes Distress

NCT03617146

COMPLETED NA

Nasogastric Decompression Following Pancreaticoduodenectomy

NCT06413888

COMPLETED Phase 2

N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy

NCT03499249

COMPLETED Phase 4

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

NCT03490513

COMPLETED Phase 2

Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers

NCT03476876

COMPLETED Phase 2

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975

COMPLETED

Cardiac Biomarkers in Patients With Single Ventricle Physiology

NCT03678909

COMPLETED

Tranexamic Acid Per Inhalation for Treatment of Pulmonary Hemorrhage in Pediatric Patients

NCT03676023

COMPLETED NA

Effect of Exercise on Genes That Control Muscle Function

NCT03414385

COMPLETED Phase 1

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

NCT03192462

COMPLETED NA

Technology to Improve the Health of Resource-poor Hispanics With Diabetes

NCT03394456

COMPLETED Early Phase 1

Entolimod, an Adjuvant for Vaccine Augmentation

NCT03063736

COMPLETED

Chronic Liver Disease in Urea Cycle Disorders

NCT03721367

COMPLETED Phase 1

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

NCT03064074

COMPLETED NA

Lifestyle Intervention to Improve Bone Quality

NCT03329963

COMPLETED NA

Effect of Monochromatic Light on Incidence of Emergence Delirium in Children

NCT03285243

COMPLETED

Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH

NCT03382951

COMPLETED

Review of Diagnostic Yield of MRI Brain Results in Children Under Age 3 Years

NCT03561168

COMPLETED Phase 2

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

NCT03093350

COMPLETED NA

Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD

NCT03064048

COMPLETED NA

Online Videos and New Feeding Content to Enhance a Current EFNEP Program

NCT03170700

COMPLETED

Long-term Lifestyle Change and Testosterone Replacement

NCT03256292

COMPLETED NA

Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study

NCT02877680

COMPLETED Phase 2

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

NCT02744430

COMPLETED NA

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

NCT03960463

TERMINATED NA

Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax

NCT02449980

COMPLETED Phase 2

Micro-mobile Foot Compression and Diabetic Foot

NCT03135535

COMPLETED Early Phase 1

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329

COMPLETED Phase 1

Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

NCT02949700

COMPLETED

Gravity Assisted Technique for Esophageal Endoscopic Submucosal Dissection (ESD)

NCT04547881

COMPLETED Phase 1

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

NCT02885974

COMPLETED NA

Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants

NCT02943746

COMPLETED NA

Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia

NCT02975973

COMPLETED

Overcoming Obstacles in Epigenetic Analysis of Human Twins

NCT04279704

TERMINATED Phase 1

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

NCT02838745

COMPLETED

Prediction of Brain Injury in Premature Infants

NCT02814383

COMPLETED Phase 4

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

NCT02933450

COMPLETED NA

Efficacy of Audio Recorded Guided Imagery vs Deep Breathing Exercises on Functional Gastrointestinal Pain Disorders

NCT03100487

COMPLETED Phase 2

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222

COMPLETED NA

Effect of Caudal and Penile Block on Hypospadias Repair Complications

NCT02851290

COMPLETED NA

Transforming Care and Payment Priorities for Vulnerable Families

NCT03416712

COMPLETED Phase 4

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

NCT02959853

COMPLETED NA

High-Risk Neuroblastoma Chemotherapy Without G-CSF

NCT02786719

COMPLETED Phase 2

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551

COMPLETED Phase 2

Using Game-based Exercise to Improve Balance in Cancer Patients

NCT02773329

TERMINATED NA

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

NCT02739347

COMPLETED NA

Effects of Diet Interventions on Monocytes in Metabolic Syndrome

NCT03591588

TERMINATED Phase 2

Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

NCT02737202

TERMINATED NA

Hummus for Health: Dietary Quality and Health Outcomes in Toddlers

NCT02696278

← Previous Page 6 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 173
Phase 2 59
Phase 3 13
Phase 4 46

What is open in the Baylor College of Medicine pipeline

93 recruiting of 616 indexed (15% open); 376 completed (61%).

Phase mix: 59 late (III/IV) vs 232 early (I/II) (early-phase heavy).

Top condition: Non-Hodgkin Lymphoma (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Baylor College of Medicine: open-pipeline peers nationwide

Peers matched on 616 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 0%5%10%15%20% Total trials Recruiting share Baylor College of MedicineUniversity of Southern CaliforniaUS Department of Veterans AffairsUniversity of RochesterJanssen Research & DevelopmentStanford UniversityBaylor UniversityCornell University59th Medical Wing
Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 616 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Baylor College of Medicine page

616 registered trials is a research-attention snapshot, not an endorsement of Baylor College of Medicine or any single study.

  • 93 of Baylor College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Hodgkin Lymphoma is the condition Baylor College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Baylor College of Medicine pipeline card: 616 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.